login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

HeartWare Ventricular Assist System shows positive performance in end-stage heart failure patients


Friday, 25 May 2012 16:46
HVAD Pump
HVAD Pump

Results of ADVANCE―a US clinical trial evaluating the use of the HeartWare Ventricular Assist System (HeartWare International) as a bridge to heart transplantation in patients with advanced heart failure―were published on 22 May ahead of print in Circulation. Data demonstrate the potential utility of the HVAD Pump to improve treatment outcomes for end-stage heart failure patients.


“With the publication of the ADVANCE trial in Circulation, cardiologists and cardiac surgeons treating advanced heart failure will now have the opportunity to thoroughly review the excellent results our investigators obtained using the HVAD Pump to bridge their patients to transplant,” said co-principal investigator Keith Aaronson, professor in the Division of Cardiovascular Medicine and medical director of the Heart Transplant Program and Center for Circulatory Support at the University of Michigan, USA.

ADVANCE studied 140 patients from 30 US hospitals who received the HeartWare investigational device. The authors noted high rates of 180-day success and survival and improvements in quality of life and functional capacity for patients with end-stage heart failure that were similar to those seen with cardiac transplantation. Success was achieved for the primary endpoint by establishing non-inferiority between the investigational device and comparator arm of the study, which was derived from contemporaneous patients from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) [p<0.0001]. Success on the primary endpoint occurred in 92.0% of the investigational device patients in the per protocol study population, 90.7% of the investigational device patients in the safety study population and 90.1% of INTERMACS control patients.

The most common adverse events were typical of those previously reported for an axial design, continuous-flow pump, and included bleeding, infections, stroke and perioperative right heart failure.


“The high rates of success and survival, as well as improvements in quality of life and functional capacity detailed in the publication, support our belief that, if approved, the HVAD would offer patients with advanced heart failure a valuable new treatment option,” said Doug Godshall, president and CEO, HeartWare. “We are working closely with the FDA as they complete their review of our premarket application application for the HeartWare Ventricular Assist System as a bridge to heart transplant and look forward to their decision.”


“As we showed at our FDA panel meeting last month, some of the more challenging adverse events we observed in this initial study cohort have improved measurably in our continued access cohort by refining post-operative management techniques and by introducing sintered inflow cannulas which appear to be contributing to decreased thromboembolic complications” said Godshall.


The HeartWare Ventricular Assist System is under FDA review for a bridge-to-transplant indication. On 25 April 2012, the FDA’s Circulatory System Devices advisory committee voted nine to two that the benefits outweigh the risks for the use of the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. The advisory committee’s recommendation, while not binding, will be considered by the FDA in its review of the premarket approval application submitted for the HeartWare Ventricular Assist System in December 2010.

HeartWare has received CE mark for the HeartWare System in the European Union.




Add New Comment

Most popular


St Jude Medical completes acquisition of CardioMEMS
Monday, 02 Jun 2014
St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014. St Jude Medical completes acquisition of CardioMEMS

FDA approves CardioMEMS heart failure system
Monday, 02 Jun 2014
The US Food and Drug Administration has approved the CardioMEMS heart failure system that measures the pulmonary artery pressures and heart rates of patients with New York Heart Association (NYHA) C... FDA approves CardioMEMS heart failure system

Friday, 04 Jul 2014
A new study suggests that transradial access in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention is associated with reduced bleeding ... Transradial access predicts survival in NSTEMI patients

Features


New approach for aortic valve replacement is feasible
Friday, 04 Jul 2014
According to a report in The Journal of Thoracic and Cardiovascular Surgery, totally endoscopic aortic valve replacement (TEAVR) is technically feasible. Lead author of the report Marco Vola talks to ... New approach for aortic valve replacement is feasible

“Interventional cardiology is losing more than 50% of the talent pool”
Thursday, 05 Jun 2014
The Women Committee of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) has been set up to attain gender equality in interventional cardiology at the professional and ... “Interventional cardiology is losing more than 50% of the talent pool”

Profiles


David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Ashok Seth
Wednesday, 12 Feb 2014
Ashok Seth is the immediate past president of Cardiological Society of India and is the principal ... Ashok Seth

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions